Effect of Vericiguat on Worsening Heart Failure in Compensated Outpatients with HFrEF: Insights from VICTOR

Journal:
Journal of the American College of Cardiology
Published:
DOI:
10.1016/j.jacc.2025.08.051
Affiliations:
26
Authors:
28
Institutions Authors Share
Merck & Co, United States of America (USA)
6.038462
0.22
Bayer, Germany
2.038462
0.07
Wroclaw Medical University, Poland
1.038462
0.04
Canadian VIGOUR Centre, U of A, Canada
1.038462
0.04
Centro Cardiovascular Colombiano Clinica Santa Maria (Clinica Cardio VID), Colombia
1.038462
0.04
Mayo Clinic, United States of America (USA)
1.038462
0.04
Tufts Medical Center, United States of America (USA)
1.038462
0.04
Stanford University, United States of America (USA)
1.038462
0.04
University of Lorraine (UL), France
1.038462
0.04
Bayer U.S., United States of America (USA)
1.038462
0.04
University of Groningen (RUG), Netherlands
1.038462
0.04
Vanderbilt University Medical Center (VUMC), United States of America (USA)
1.038462
0.04
University of Colorado Anschutz Medical Campus (CU Anschutz), United States of America (USA)
1.038462
0.04
The University of North Carolina at Chapel Hill (UNC), United States of America (USA)
1.038462
0.04
Inova Heart and Vascular Institute, United States of America (USA)
1.038462
0.04
Duke University Health System, United States of America (USA)
1.038462
0.04
Bayer Consumer Care AG, Switzerland
1.038462
0.04
University of Milano-Bicocca (UNIMIB), Italy
0.538462
0.02
Baylor Scott & White Health, United States of America (USA)
0.538462
0.02
University of Mississippi (Ole Miss), United States of America (USA)
0.538462
0.02
National Heart Centre Singapore (NHCS), Singapore
0.538462
0.02
Duke-NUS Medical School, Singapore
0.538462
0.02
Azienda Ospedaliera Papa Giovanni XXIII, Italy
0.538462
0.02
San Raffaele University of Rome (UniSanRaffaele), Italy
0.371795
0.01
IRCCS San Raffaele Hospital (HSR), Italy
0.371795
0.01
San Raffaele S.p.A., Italy
0.371795
0.01